Replies to post #247537 on Biotech Values

[swampboots]

Regarding this type of bioengineering involving white blood cells , I am not qualified to place this news within the landscape of previous scientific pathways, but because of the high cost of personalized targeting
for each patient, the article does offer the fairy godmother wish that a Saviour would come along to replicate this personalized patient success with an off the shelf methodology. at much lower cost.
Yet the aforementioned I referred to, is still a lavish wish, involving macrophages, as the substance of all this possible road to success to eliminate cancer has not gone beyond in vivo.

[jondoeuk]

CARM is in the clinic with an auto HER2-targeted CAR-M therapy, with others in development, including for non-oncology indications. They are working on off-the-shelf, in vivo (partnered with MRNA) and next-gen versions, such as CARs with improved phagocytosis, CRISPR engineered, and synthetic cytokine switch receptors https://jitc.bmj.com/node/29507.full https://jitc.bmj.com/content/10/Suppl_2/A396

Two others (both private and off-the-shelf) working on CAR-M's (and NK cells) are Shoreline Bio (partnerships with GILD's Kite and BGNE) and CellOrigin Bio. Preclinical data for both https://aacrjournals.org/cancerres/article/83/7_Supplement/4059/723298/Abstract-4059-Developing-an-allogeneic-iPSC https://ashpublications.org/blood/article/140/Supplement%201/9238/487745/The-Second-Generation-of-Human-iPSC-Derived-CAR

I know Shoreline plan to test both innate cells https://aacrjournals.org/cancerres/article/82/12_Supplement/553/700580